Patents Examined by Lila Feisee
  • Method for reducing the severity of gastro-intestinal damage
    Patent number: 5888978
    Abstract: The present invention provides methods for reducing the severity of GI damage in an individual by administering a cytokine regulatory agent to an individual that is susceptible to developing such damage.
    Type: Grant
    Filed: September 12, 1995
    Date of Patent: March 30, 1999
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Paul Omholt, Ronald R. Tuttle
  • DNA encoding human a erythropoietin analog
    Patent number: 5888772
    Abstract: Analogs of human erythropoietin, including the ?X.sup.33, Cys.sup.139, des-Arg.sup.166 ! and ?Cys.sup.139, des-Arg.sup.166 ! analogs, as well as methods for making and using such analogs and pharmaceutical compositions containing the same.
    Type: Grant
    Filed: October 23, 1995
    Date of Patent: March 30, 1999
    Assignee: Abbott Laboratories
    Inventors: Gregory F. Okasinski, Peter J. DeVries, Berry S. Mellovitz, Joseph L. Meuth, Verlyn G. Schaefer
  • Human IL-2 receptor .gamma.-chain molecule antibody
    Patent number: 5889160
    Abstract: The present invention relates to an IL-2 receptor .gamma. chain molecule, a DNA-sequence encoding the IL-2 receptor .gamma. chain molecule, a vector possessing said DNA-sequence, a cell transformed with said vector, a method for the production of an IL-2 receptor .gamma. chain molecule by culturing of said cell, an immune response regulatory agent comprising an IL-2 receptor .gamma. chain molecule and an antibody to an IL-2 receptor .gamma. chain molecule.
    Type: Grant
    Filed: July 30, 1997
    Date of Patent: March 30, 1999
    Assignees: Ajinomoto Co., Inc., Kazuo Sugamura
    Inventors: Kazuo Sugamura, Toshikazu Takeshita, Hironobu Asao, Masataka Nakamura, Toshiro Shimamura, Manabu Suzuki, Junji Hamuro
  • Melatonin 1A receptor gene regulatory regions and uses thereof
    Patent number: 5889177
    Abstract: Disclosed are DNAs encoding melatonin 1a receptor gene promoter regions, recombinant polypeptides expressed from such DNAs, and methods of using such expression constructs to screen for promoter activators or inhibitors. Transcriptional activators are useful as therapeutics to reentrain endogenous melatonin rhythms as a means of treating circadian rhythm disorders in humans and control reproductive cycles in seasonally breeding animals. Transcriptional inhibitors are useful as therapeutics to control the initiation or timing of puberty in humans.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: March 30, 1999
    Assignee: The General Hospital Corporation
    Inventor: Steven M. Reppert
  • In vitro method for diagnosing benign Barrett's Epithelium
    Patent number: 5888743
    Abstract: This invention relates to a method for the diagnosis of benign Barrett's Epithelium and Barrett's-derived adenocarcinoma. The method of diagnosis comprises contacting a monoclonal antibody which reacts with benign Barrett's Epithelium cells and Barrett's-derived adenocarcinoma cells, but does not react with normal esophageal epithelium cells, squamous carcinoma cells, cardia cells or gastric mucosa cells and detecting immunoreactivity. Immunoreactivity indicates a positive diagnosis Barrett's Epithelium or Barrett's-derived adenocarcinoma.
    Type: Grant
    Filed: June 23, 1995
    Date of Patent: March 30, 1999
    Inventor: Kiron M. Das
  • Corticotropin-releasing hormone receptor
    Patent number: 5888811
    Abstract: A novel human corticotropin releasing hormone (CRH) receptor which is a splice variant of the human CRH.sub.2 receptor subfamily and is designated human CRHR2.gamma.. Fragments of CRHR2.gamma.. Nucleic acid molecules which encode CRHR2.gamma. and fragments, expression vectors comprising the nucleic acid molecules, and host cells containing the expression vectors. Antibodies and antibody fragments capable of binding the novel receptor. Nucleic acid molecules capable of hybridizing with the above nucleic acid molecules. Use of the novel receptor and receptor fragments, antibodies and antibody fragments in testing compounds for CRH antagonist activity and in treating diseases.
    Type: Grant
    Filed: May 21, 1997
    Date of Patent: March 30, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Brian Lee Largent, Ai-Ru Chen, Walter Alan Kostich, Karen Marie Sperle
  • Treatment for insulin dependent diabetes
    Patent number: 5888507
    Abstract: A method for the prevention of insulin dependent (type I) diabetes. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: March 30, 1999
    Assignee: Biogen, Inc.
    Inventor: Linda C. Burkly
  • Regeneration of oligodendrocytes
    Patent number: 5885584
    Abstract: The invention concerns a process for improving the regeneration of oligodendrocytes, in particular of human oligodendrocytes, in which oligodendrocytes are treated in cell culture with nerve growth factor (NGF) or active fragments of NGF. Furthermore a composition is disclosed for treating diseases in which a demyelination of nerve fibres occurs which contains NGF or an active fragment thereof as the active substance, if desired, together with the usual pharmaceutical vehicles, auxiliary substances, fillers and diluents.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: March 23, 1999
    Assignees: Boehringer Mannheim GmbH, Max-Planck-Gesellschaft zur Forderung der Wissenschaften, E.V.
    Inventors: Hans-Hinrich Althaus, Jurgen Unger, Ilse Bartke
  • Candida albicans integrin-like protein
    Patent number: 5886151
    Abstract: An isolated and purified DNA molecule encoding Candida albicans protein with integrin-like motifs, the protein itself, antibodies thereto, and methods of use, are provided.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: March 23, 1999
    Assignee: Regents of the University of Minnesota
    Inventors: Margaret K. Hostetter, Cheryl A. Gale, Catherine M. Bendel, Nian-jun Tao, Kathleen Kendrick
  • Single-chain double-alpha peptide
    Patent number: 5883073
    Abstract: The invention is directed to a glycosylated or nonglycosylated protein which is composed of the amino acid sequence of a first .alpha. subunit common to the glycoprotein hormones linked covalently, optionally through a linker moiety, to the amino acid sequence of a second .alpha. subunit of said hormones, wherein said first and second .alpha. subunits consist of the native amino acid sequences or variants of said amino acid sequences. These proteins are useful as agonists or antagonists of glycoprotein hormone activity.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: March 16, 1999
    Assignee: Washington University
    Inventors: Irving Boime, David Ben-Menahem
  • Compositions and methods for preventing and treating allograft rejection
    Patent number: 5883082
    Abstract: Compositions and methods are provided for the prevention and treatment of allograft rejection. Compositions are provided which comprise an antisense oligonucleotide targeted to a nucleic acid sequence encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, or endothelial leukocyte adhesion molecule-1 in combination with an immunosuppressive agent. Methods of preventing or treating allograft rejection by treating an allograft recipient with such a composition are provided. Methods for preventing allograft rejection comprising perfusion of the graft are also provided.
    Type: Grant
    Filed: November 23, 1994
    Date of Patent: March 16, 1999
    Assignees: ISIS Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: C. Frank Bennett, Stanislaw M. Stepkowski
  • Method and system for protein modeling
    Patent number: 5884230
    Abstract: A method in a computer system for modeling a three-dimensional structure of a model protein is provided. In one embodiment, the modeling is based upon a three-dimensional structure of a template protein and an amino acid sequence alignment of the model protein and the template protein. For each amino acid in the model protein, when the template protein has an amino acid aligned with the amino acid of the model protein, the position of the backbone atom of the amino acid of the model protein is established based on the position of a topologically equivalent backbone atom in the aligned amino acid of the template protein. In another embodiment, the modeling of a variable region of the model protein is based on a collection of .psi. and .phi. angle values for amino acid pairs in a family of proteins. In a further embodiment, these .psi. and .phi.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: March 16, 1999
    Assignee: Immunex Corporation
    Inventors: Subhashini Srinivasan, Padmanaban Sudarsanam
  • Human DNA sequence encoding a kidney ATP-dependent potassium channel
    Patent number: 5882873
    Abstract: The present invention comprises human DNA compositions encoding proteins that confer potassium channel activity to membranes or recipient cell lines. The DNA compositions include structural genes coding for the potassium channel proteins, expression and replication plasmids or vectors containing the structural genes and host cells expressing those genes. Methods of screening compounds for potassium channel modulating activity are also described.
    Type: Grant
    Filed: August 9, 1995
    Date of Patent: March 16, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Michael Jerome Bienkowski, Vincent Edward Groppi, Jr.
  • Human transaldolase: an autoantigen with a function in metabolism
    Patent number: 5879909
    Abstract: Transaldolase is an enzyme which acts as an autoantigen in immune-related neurodegenerative diseases, particularly multiple sclerosis. Human transaldolase, the DNA coding therefore, peptides derived therefrom, and DNA control elements associated therewith and anti-transaldolase antibodies are disclosed. These compositions are useful in methods such as immunoassays for detecting subjects making anti-transaldolase antibodies and diagnosing the neurodegenerative disease.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: March 9, 1999
    Assignee: The Research Foundation of State University of New York
    Inventor: Andras Perl
  • Method of screening for inhibitors of human thyrotropin releasing hormone (TRH) receptor
    Patent number: 5879896
    Abstract: A human receptor protein capable of binding TRH, a DNA coding for said protein, use of the proetein and DNA, a method for preparing said protein, and antibodies to the protein are described.The human TRH receptor protein and the DNA coding for the protein of the present invention are useful as (1) a diagnostic composition for neuropathy (particularly, dementia), (2) a pharmaceutical composition for neuropathy and (3) a material used for screening a TRH receptor agonist or antagonist.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: March 9, 1999
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shuji Hinuma, Masaki Hosoya, Haruo Onda
  • Cell surface protein expressed on human cortical thymocyte and their use
    Patent number: 5879911
    Abstract: A novel protein which is glycoprotein with 120,000 molecular weight and is expressed on T lymphoblastic lymphoma and leukemia cells, is useful in the diagnosis of T lymphoblastic lymphoma and leukemia.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: March 9, 1999
    Assignee: Seong Hoe Park
    Inventors: Seong Hoe Park, Young Mee Bae
  • Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
    Patent number: 5879898
    Abstract: There is marked over-expression of multiple spliced variants of the CD44 gene in tumor compared to counterpart normal tissue. This observation forms the basis of a method of diagnosing neoplasia by analysis of a sample of body tissue or body fluid or waste product. A new exon 6 of 129 bp has been located and sequenced. Antibodies specific to the exon have been prepared and are claimed as new compounds suitable for use in the detection of CD44 proteins and for the in vivo imaging and therapy of tumors.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: March 9, 1999
    Assignee: ISIS Innovation Limited
    Inventors: David Tarin, Yasuhiro Matsumura
  • Human trk receptors and neurotrophic factor inhibitors
    Patent number: 5877016
    Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns inmunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: March 2, 1999
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
  • Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
    Patent number: 5877295
    Abstract: The present invention is based on the novel observation that upon stimulation of resting myeloid cells, not all of the Mac-1 molecules expressed by the cell become activated. Only select subpopulations of Mac-1 molecules are activated and become capable of binding ligand. Further, the activated Mac-1 molecules were found to possess activation specific epitopes which distinguishes them from non-activated Mac-1 molecules. Based on these observations antibodies are described which selectively bind activated Mac-1 molecules but are substantially incapable of binding non-activated Mac-1.
    Type: Grant
    Filed: August 22, 1995
    Date of Patent: March 2, 1999
    Assignee: The Center for Blood Research
    Inventors: Michael Diamond, Timothy A. Springer
  • Antigenic regions of tumor-liberated particles (TLP) complexes and antibodies against the same
    Patent number: 5877294
    Abstract: Peptides comprised within the 100 KDa protein of the TLP complex (i.e., released proteins from tumors) having antigenic activity as well as antibodies thereof, able to react with TLP for diagnostic and clinical purposes.
    Type: Grant
    Filed: June 19, 1996
    Date of Patent: March 2, 1999
    Assignee: Instituto Farmacoterapico Italiano S.p.A.
    Inventor: Giulio Tarro